{"id":"W4407265667","doi":"10.1093/ndt/gfaf022","title":"COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics","year":2025,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Hormonal Regulation and Hypertension","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Relypsa; American Regent; Bayer, United Kingdom; Chugai Pharmaceutical; MannKind Corporation; Cytokinetics; Fresenius Medical Care North America; Astellas Pharma; Novo Nordisk; McMaster University; Daiichi-Sankyo; Impulse Dynamics; Idorsia Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Akebia Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Alexion Pharmaceuticals; Alnylam Pharmaceuticals; Bayer; Gilead Sciences; Bayer HealthCare; European Commission; Sanofi; Amgen; Pfizer","keywords":"Empagliflozin; Medicine; Placebo; Clinical endpoint; Internal medicine; Kidney disease; Confidence interval; Hazard ratio; Randomized controlled trial; Type 2 diabetes; Diabetes mellitus; Randomization; Endocrinology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001937308,0.0009368048,0.001839627,0.0002735701,0.0003061867,0.0009837727,0.0005950786,0.001124451,0.005028969],"category_scores_gemma":[0.002680061,0.000407921,0.001747664,0.0003263424,0.0003862081,0.0006212471,0.0005623196,0.001936286,0.0004188803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003420669,"about_ca_system_score_gemma":0.0005815008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008100561,"about_ca_topic_score_gemma":0.001545749,"domain_scores_codex":[0.9991052,0.0004201454,0.00008823581,0.0002106293,0.0001017853,0.00007391682],"domain_scores_gemma":[0.9985397,0.0003162518,0.0004697936,0.0001371224,0.0001543495,0.0003827212],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9707665,0.003861307,0.006992718,0.0008850134,0.002612431,0.00003038124,0.00005039426,0.0002928328,0.002175069,0.000111234,0.00115085,0.01107126],"study_design_scores_gemma":[0.8632282,0.07845588,0.04768214,0.0001649285,0.005602377,0.0001313051,0.00004901144,0.001210561,0.0008653682,0.0002636816,0.002297496,0.00004918046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850027,0.004950339,0.0005531065,0.0004691102,0.0002288407,0.002390514,0.002607186,0.00008323674,0.003715034],"genre_scores_gemma":[0.9898044,0.001003458,0.00169757,0.0007545406,0.0003731127,0.002145936,0.002573592,0.00001219921,0.001635258],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005028969,"threshold_uncertainty_score":0.01682353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02758190397293211,"score_gpt":0.3261872990378171,"score_spread":0.298605395064885,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}